Our 2023 Event has Concluded

For those who attended, thank you for an incredible event. We are looking forward to returning in September 2024.

C5’s Life Sciences IP Summit features speakers from the pharma, biotech and medical device industries that provide practical insights on procuring and maintaining patents in the Unitary Patent era.

2023 Co-Chairs

Liz Cohen

Joint Managing Partner
Bristows LLP


Dr. Andreas von Falck

Hogan Lovells International LLP

“I’m very much looking forward to co-chairing C5’s 21st Annual Life Sciences IP Summit in Munich and hearing from our experienced panelists on current challenges faced by the Life Sciences Industry. No doubt the opening of the UPC will stimulate a number of interesting debates in which we can all participate and learn.”

“C5’s 2023 edition of the Life Sciences IP Summit in Munich will take place just a few months after the Unified Patent Court opens its doors on June 1, 2023. This conference is a perfect opportunity for both outside counsel and in-house counsel to compare notes, meet and learn from our wonderful faculty, which will include members of the UPC, and leading practitioners in the field. Attend this fall to learn first-hand what to expect from the new court!”

The Unitary Patent is Transforming the Calculus of Patenting in Europe – and the Unified Patent Court Commences on 1st June – Are You Prepared?

It is a new dawn for European patents. The creation of a new Unified Patent Court and a new patent with unitary effect will fundamentally change the international patent prosecution and litigation landscape for years to come. To be competitive in an already competitive market, you must be ready for these changes.

C5 invites you to Munich – home of one of the Central Division UPC Courts of First Instance – to attend our 22nd annual Life Sciences IP Summit at a time when the industry is on the precipice of such significant change. Our speakers from the pharma, biotech and medical device industries will provide practical insights on procuring and maintaining patents in the Unitary Patent era, as well as provide you with offensive and defensive patent litigation strategies for the new Unified Patent Court.

  • Understand the UPC Approach for Handling Evidence, Expert Witnesses, and Damages
  • Compare and Contrast How Preliminary Injunctions are Managed in the UPC vs. National Courts
  • Strategize on Effective Patent Lifecycle Management Amidst New EU Pharma Law Reform
  • Avoid the Top 10 Drafting Mistakes Impacting Life Science Patent Enforcement in Europe
  • Apply the Latest EBA Decisions on Plausibility and Priority to Your Litigation Strategy
  • Comprehend the Implications of Proposed Changes to the Scope of the Bolar Exemption
  • Navigate the Unique Challenges of Patenting and Protecting Personalized Medicine
Quote Icon

Another great C5 conference. Good variety of attendees and topics.

Robin Ellis, Head of IP Product, Sandoz
Quote Icon

Good meeting; I enjoyed it a lot, including both the talks and the social side.

Andrew Bentham, Patent Attorney, JA Kemp
Quote Icon

Again, very good speakers from all over Europe and the US.

Chrisoph Rehfuss, Head of IP, Sotio
  • Ablynx NV
  • Alkermes Pharma Ireland Ltd
  • AstraZeneca AB
  • Benitec Biopharma Limited
  • Biotronik
  • Boehringer Ingelheim
  • Celltrion
  • Chiesi Farmaceutici Spa
  • EGIS Pharmaceuticals PLC
  • Esteve Group
  • European Patent Office
  • F. Hoffmann-La Roche Ltd
  • Federal Agency for Nature
  • Finnish Patent and Registration Office
  • Fresenius Medical Care AG & Co
  • Fresenius Medical Care AG & Co. KG Aa
  • Geistlich Pharma AG
  • Genmab AS
  • German Patent & Trade Mark Office
  • GlaxoSmithKline
  • Groupe Sanofi
  • Helsinn Healthcare SA
  • JETRO Duesseldorf
  • Leukocare AG
  • Linde Healthcare
  • Merus NV
  • Novartis Pharma AG
  • Novo Nordisk A/S
  • PARI Pharma GmbH
  • Patent Office Denmark
  • Patents Office Ireland
  • Sandoz International GmbH
  • Sanofi-Aventis Deutschland GmbH
  • Silence Therapeutics Plc
  • Swiss Federal Institute of Intellectual Property
  • Teva Pharmaceuticals Ltd
  • TiGenix NV
  • UCB Chong Kun Dang pharm.
  • Valea AB
  • Zacco Denmark AS
  • Zealand Pharma AS
  • Zentiva Group
Past Attendees by Country
Representatives from corporate organisations from functions including:
  • Patent Counsel
  • Head of IP
  • VP-Intellectual Property
  • Scientific Director
  • Senior IP Counsel
  • Associate General Counsel IP
  • European Patent Attorney
  • Head of Legal Affairs
  • Principal Patent Examiner
  • Vice President & Chief Counsel – IP
  • VP Head Group Intellectual Property
  • Head of Global Strategy
  • Direct of Patent and Design Rights
  • CTO
  • Product Manager
  • Director Innovation, IP and Portfolio Management
  • Director IP Strategy & Projects
  • R&D Patent Manager
  • Technology Development Manager
  • Associate VP & Director of Technology Licensing & Commercialization
Legal Practitioners
  • Intellectual Property and Patent
  • Life Sciences
  • European Patent
  • US Patent
Related Conferences
Event Thumbnail Image
Event Thumbnail Image
Event Thumbnail Image